-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SY-104 in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SY-104 in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SY-104 in Multiple Myeloma (Kahler Disease) Drug Details: SY-104...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SY-104 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SY-104 in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SY-104 in Sarcomas Drug Details: SY-104 is under development for the treatment...
-
Product Insights
Myxoid Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Myxoid Liposarcoma - Drugs In Development, 2023’, provides an overview of the Myxoid Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myxoid Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Round Cell Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Round Cell Liposarcoma - Drugs In Development, 2023’, provides an overview of the Round Cell Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Round Cell Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Synovial Sarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Synovial Sarcoma - Drugs In Development, 2023’, provides an overview of the Synovial Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Liposarcoma - Drugs In Development, 2023’, provides an overview of the Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liposarcoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of...
-
Product Insights
Non-Rhabdomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Rhabdomyosarcoma - Drugs In Development, 2023’, provides an overview of the Non-Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...